| Category | Sub (×) | Offered | Bid For |
|---|---|---|---|
| QIB | — | Not more than 50% of the Offer | — |
| NII / HNI (Total) | — | Not less than 15% of the Offer | — |
| Retail Investors | — | Not less than 35% of the Offer | — |
| Market Maker * | 1× | — | — |
| Total ** | — | — | — |
| Metric | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 1911.80 | 1369.00 | 1098.20 |
| PAT | 436.70 | 249.60 | 156.10 |
| EBITDA | 663.30 | 452.10 | 297.60 |
| Net Worth | 1953.60 | 1512.80 | 1258.40 |
| Total Assets | 2792.10 | 2300.10 | 1871.80 |
| Reserves | 1915.20 | 1495.20 | 1243.40 |
| Borrowings | 221.70 | 230.50 | 228.10 |
Incorporated in September 1995, Encube Ethicals Limited is a global pharmaceutical formulations company specializing in topical and transdermal dosage forms, serving 50 countries, including regulated markets such as the United States, the UK, Europe, and India. The company operates through three integrated business verticals: Global Generics, Global CDMO (Contract Development and Manufacturing Organization), and India Branded Formulations, providing end-to-end capabilities across research & development, formulation development, manufacturing, regulatory compliance, and commercialization. It is one of the fastest-growing players in the US topical generics market and has a strong presence in regulated international markets.
Encube operates large-scale regulatory-approved manufacturing facilities supported by advanced R&D infrastructure, a robust innovation pipeline, and long-standing relationships with leading global pharmaceutical companies. The company also markets branded topical products in India through an established distribution network.
Encube focuses on innovation, quality, regulatory compliance, and customer-centric product development.
As of March 31, 2026, the company had 1,695 permanent employees and 982 factory workers across production, R&D, quality, supply chain, finance, IT, and commercial functions.
Strengths